By: IPP Bureau
Last updated : May 15, 2026 8:13 am
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Cipla Limited announced its audited consolidated financial results for Q4 and FY26, reporting its highest-ever annual revenue driven by strong performance across India, Africa, and emerging markets businesses.
For Q4 FY26, the company reported income from operations of Rs. 6,541 crore. EBITDA stood at Rs. 997 crore with an EBITDA margin of 15.2%, while profit after tax (PAT) came in at Rs. 555 crore.
For FY26, Cipla reported total income from operations of Rs. 28,163 crore, reflecting 2% year-on-year growth. EBITDA stood at Rs. 5,925 crore with margins of 21%, while PAT reached Rs. 3,879 crore.
The One India business recorded strong momentum with 15% YoY growth during Q4 FY26. The business crossed the Rs. 12,500 crore annual revenue milestone, supported by robust growth in branded prescription therapies, trade generics, and consumer health products.
Key therapies including respiratory, urology, anti-diabetes, and cardiac segments posted double-digit growth. Foracortcrossed the Rs. 1,000 crore revenue milestone, while Dytor emerged as a Rs. 650 crore-plus cardiac brand.
North America business delivered quarterly revenue of US$ 155 million and annual revenue of US$ 780 million, supported by demand for differentiated products and stable base business performance.
During the year, Cipla advanced several key assets including Liraglutide, Nintedanib, and Dapagliflozin. The company also received regulatory approval for the first AB-rated generic gVentolin with CGT, marking the first commercial metered-dose inhaler manufactured from its U.S. facility.
The One Africa business recorded 14% quarterly growth and 7% annual growth in USD terms, supported by new launches and expansion of the OTC portfolio.
Emerging Markets and Europe business crossed the US$ 400 million annualized revenue milestone, supported by expansion across direct-to-market and B2B categories.
On the regulatory front, the US Food and Drug Administration completed inspections at Cipla’s manufacturing facilities in Bommasandra, Sitec, and Medispray, with all facilities receiving either Voluntary Action Indicated (VAI) or No Action Indicated (NAI) classifications.
Commenting on the performance, Achin Gupta, MD and Global CEO of Cipla Limited, said the company continued to make considerable progress across focused markets despite near-term challenges in certain regions.